Market Place
Sourcing Support
IDEAYA Biosciences Reports Q2 2024 Results And Business Update
06 Aug 2024 //
PR NEWSWIRE
Ideaya announces results for darovasertib ph 2 IST in neoadjuvant uveal at ASCO
05 Jun 2024 //
PHARMABIZ
IDEAYA`s Darovasertib Uveal Melanoma, Neoadjuvant Data At ASCO
03 Jun 2024 //
PR NEWSWIRE
Ideaya Darovasertib Uveal Summary: Ph2 Neoadjuvant Asco Oral Presentation
23 May 2024 //
PR NEWSWIRE
IDEAYA`s Darovasertib Uveal Melanoma Data in ASCO Oral Session
24 Apr 2024 //
PR NEWSWIRE
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023
17 Oct 2023 //
PR NEWSWIRE
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib
16 Oct 2023 //
PR NEWSWIRE
IDEAYA Announces First-Patient-In for Phase 2 Evaluating Darovasertib
16 Aug 2023 //
PRESS RELEASE
IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1
22 Jun 2023 //
PRESS RELEASE
IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer
16 May 2023 //
PRESS RELEASE
IDEAYA Receives Fast Track Designation for Darovasertib with Crizotinib
05 Dec 2022 //
PRNEWSWIRE
Ideaya reports positive Phase II data for MUM combination therapy
12 Sep 2022 //
CLINICALTRIALSARENA
IDEAYA Announces 1st Patient in for PI Trial Evaluate Darovasertib Monotherapy
06 Sep 2022 //
PRNEWSWIRE
IDEAYA, Pfizer Expand Trial Collaboration for Darovasertib and Crizotinib
14 Mar 2022 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.